{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:52:45Z","timestamp":1791910365902,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003509","name":"\u00d6rebro University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003509","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) leads to multiple metabolic changes, reduction in glucose levels and body weight are well established. In people with type 2 diabetes, GLP-1 RAs reduce the risk of cardiovascular (CV) disease and may also potentially represent a treatment for fatty liver disease. The mechanisms behind these effects are still not fully elucidated. The aim of the study was to investigate whether treatment with liraglutide is associated with favourable metabolic changes in cases of both CV disease and fatty liver disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In a prespecified post-hoc analysis of a double-blind, placebo-controlled trial in 62 individuals with type 2 diabetes (GLP-1 RA liraglutide or glimepiride, both in combination with metformin), we evaluated the changes in plasma molecular lipids and polar metabolites after 18\u00a0weeks of treatment. The lipids and polar metabolites were measured by using ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 340 lipids and other metabolites were identified, covering 14 lipid classes, bile acids, free fatty acids, amino acids and other polar metabolites. We observed more significant changes in the metabolome following liraglutide treatment compared to with glimepiride, particularly as regards decreased levels of cholesterol esters hexocyl-ceramides, lysophosphatidylcholines, sphingolipids and phosphatidylcholines with alkyl ether structure. In the liraglutide-treated group, lipids were reduced by approximately 15% from baseline, compared to a 10% decrease in the glimepiride group. At the pathway level, the liraglutide treatment was associated with lipid, bile acid as well as glucose metabolism, while glimepiride treatment was associated with tryptophan metabolism, carbohydrate metabolism, and glycerophospholipid metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Compared with glimepiride, liraglutide treatment led to greater changes in the circulating metabolome, particularly regarding lipid metabolism involving sphingolipids, including ceramides. Our findings are hypothesis-generating and shed light on the underlying biological mechanisms of the CV benefits observed with GLP-1 RAs in outcome studies. Further studies investigating the role of GLP-1 RAs on ceramides and CV disease including fatty liver disease are warranted.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> NCT01425580<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01431-2","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T14:03:36Z","timestamp":1639749816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-1682","authenticated-orcid":false,"given":"J.","family":"Jendle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hy\u00f6tyl\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ore\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"1","key":"1431_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27(1):22\u201341. https:\/\/doi.org\/10.1016\/j.cmet.2017.08.002.","journal-title":"Cell Metab"},{"issue":"11","key":"1431_CR2","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","volume":"126","author":"ME Pich\u00e9","year":"2020","unstructured":"Pich\u00e9 ME, Tchernof A, Despr\u00e9s JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477\u2013500. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316101.","journal-title":"Circ Res"},{"issue":"2","key":"1431_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/cvr\/cvn074","volume":"79","author":"DJ Chess","year":"2008","unstructured":"Chess DJ, Stanley WC. Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res. 2008;79(2):269\u201378. https:\/\/doi.org\/10.1093\/cvr\/cvn074.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"1431_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313\u201324. https:\/\/doi.org\/10.1016\/S2213-8587(18)30154-2.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1431_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-8587(17)30236-X","volume":"6","author":"DH Bessesen","year":"2018","unstructured":"Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018;6(3):237\u201348. https:\/\/doi.org\/10.1016\/S2213-8587(17)30236-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1431_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck M, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"10019","key":"1431_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"issue":"9","key":"1431_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0028-1082326","volume":"40","author":"T Nystrom","year":"2008","unstructured":"Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res. 2008;40(9):593\u2013606. https:\/\/doi.org\/10.1055\/s-0028-1082326.","journal-title":"Horm Metab Res"},{"key":"1431_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010.","journal-title":"Mol Metab"},{"issue":"20","key":"1431_CR10","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1016\/j.jacc.2021.03.314","volume":"77","author":"N Akawi","year":"2021","unstructured":"Akawi N, Checa A, Antonopoulos AS, Akoumianakis I, Daskalaki E, Kotanidis CP, et al. Fat-secreted ceramides regulate vascular redox state and influence outcomes in patients with cardiovascular disease. J Am Coll Cardiol. 2021;77(20):2494\u2013513. https:\/\/doi.org\/10.1016\/j.jacc.2021.03.314.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1431_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jash.2018.02.003","volume":"12","author":"J Jendle","year":"2018","unstructured":"Jendle J, Fang X, Cao Y, Boj\u00f6 L, Nilsson BK, Hedberg F, et al. Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. J Am Soc Hypertens. 2018;12(5):346\u201355. https:\/\/doi.org\/10.1016\/j.jash.2018.02.003.","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"1431_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.58","volume":"2","author":"T Nystrom","year":"2019","unstructured":"Nystrom T, Santos-Pardo I, Fang X, Cao Y, Hedberg F, Jendle J. Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: a randomized, open, parallel-group study. Endocrinol Diabetes Metab. 2019;2(2): e00058. https:\/\/doi.org\/10.1002\/edm2.58.","journal-title":"Endocrinol Diabetes Metab"},{"key":"1431_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fendo.2017.00325","volume":"8","author":"T Nystrom","year":"2017","unstructured":"Nystrom T, Santos-Pardo I, Hedberg F, Wardell J, Witt N, Yang C, et al. Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin: a randomized open parallel-group study. Front Endocrinol. 2017;8:325. https:\/\/doi.org\/10.3389\/fendo.2017.00325.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1431_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","volume":"226","author":"J Folch","year":"1957","unstructured":"Folch J, Lees M, Stanley GHS. A simple method for the isolationa and purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497\u2013509.","journal-title":"J Biol Chem"},{"key":"1431_CR15","doi-asserted-by":"publisher","first-page":"105935","DOI":"10.1016\/j.envint.2020.105935","volume":"143","author":"A McGlinchey","year":"2020","unstructured":"McGlinchey A, Sinioja T, Lamichhanec S, Partho S, Bodin J, Siljander H, et al. Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes. Environ Int. 2020;143:105935. https:\/\/doi.org\/10.1016\/j.envint.2020.105935.","journal-title":"Environ Int"},{"issue":"10","key":"1431_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00216-019-02263-6","volume":"412","author":"S Salihovic","year":"2020","unstructured":"Salihovic S, Dickens A, Schoultz I, Fart F, Sinisalu L, Lindeman T, et al. Simultaneous determination of per- and polyfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2020;412(10):2251\u20139.","journal-title":"Anal Bioanal Chem"},{"key":"1431_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab412","author":"L Andersson","year":"2021","unstructured":"Andersson L, Cinato M, Mardani I, Miljanovic A, Arif M, Koh A, et al. Glucosylceramide synthase deficiency in the heart compromises \u03b21-adrenergic receptor trafficking. Eur Heart J. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab412.","journal-title":"Eur Heart J"},{"issue":"W1","key":"1431_CR18","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gky310","volume":"46","author":"J Chong","year":"2018","unstructured":"Chong J, Soufan O, Li C, Caraus L, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018;46(W1):W486\u201394. https:\/\/doi.org\/10.1093\/nar\/gky310.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1431_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010883","volume":"5","author":"WE Gall","year":"2010","unstructured":"Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE. 2010;5(5): e10883. https:\/\/doi.org\/10.1371\/journal.pone.0010883.","journal-title":"PLoS ONE"},{"issue":"4","key":"1431_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124079","volume":"4","author":"JL Horton","year":"2019","unstructured":"Horton JL, Davidson MT, Kurishima C, Vega RB, Powers JC, Matsuura TR, Petucci C, et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight. 2019;4(4): e124079. https:\/\/doi.org\/10.1172\/jci.insight.124079.","journal-title":"JCI Insight"},{"issue":"4","key":"1431_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"issue":"13","key":"1431_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JB, Stewart I, Willems S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes a meta-analysis. JAMA. 2016;316(13):1383\u201391. https:\/\/doi.org\/10.1001\/jama.2016.14568.","journal-title":"JAMA"},{"issue":"1","key":"1431_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/JOE-16-0478","volume":"233","author":"M Buganova","year":"2017","unstructured":"Buganova M, Pelantova H, Holubova M, \u0160ediv\u00e1 B, Malet\u00ednsk\u00e1 L, \u017delezn\u00e1 B, et al. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. J Endocrinol. 2017;233(1):93\u2013104. https:\/\/doi.org\/10.1530\/JOE-16-0478.","journal-title":"J Endocrinol"},{"issue":"1","key":"1431_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12933-019-0945-7","volume":"18","author":"N Peradze","year":"2019","unstructured":"Peradze N, Farr OM, Perakakis N, Lazaro I, Sala-Vila A, Mantzoros CS. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc Diabetol. 2019;18(1):141. https:\/\/doi.org\/10.1186\/s12933-019-0945-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1431_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, Soderlund S, Bjornson E, Pietil\u00e4inen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84\u201394. https:\/\/doi.org\/10.1111\/dom.13487.","journal-title":"Diabetes Obes Metab"},{"key":"1431_CR26","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews D, Frid A, Hermansen K, During M, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment, is primarily due to a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163\u201372.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1431_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1161\/ATVBAHA.115.305479","volume":"35","author":"GM Dallinga-Thie","year":"2015","unstructured":"Dallinga-Thie GM, Nieuwdorp M. GLP1, an important regulator of intestinal lipid metabolism. Arterioscler Thromb Vasc Biol. 2015;35(5):1048\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.115.305479.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1431_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2174\/1871529x14666140505125300","volume":"14","author":"S Farr","year":"2014","unstructured":"Farr S, Taher J, Adeli K. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Cardiovasc Hematol Disord Drug Target. 2014;14(2):126\u201336. https:\/\/doi.org\/10.2174\/1871529x14666140505125300.","journal-title":"Cardiovasc Hematol Disord Drug Target"},{"key":"1431_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002395","volume":"9","author":"EH Zobel","year":"2021","unstructured":"Zobel EH, Wretlind A, Ripa RS, Curovic VR, von Scholten B, Suvitaival T, et al. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diab Res Care. 2021;9: e002395. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002395.","journal-title":"BMJ Open Diab Res Care"},{"issue":"7","key":"1431_CR30","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1172\/JCI97949","volume":"128","author":"M Trayssac","year":"2018","unstructured":"Trayssac M, Hannun YA, Obeid LM. Role of sphingolipids in senescence: implication in aging and age-related diseases. J Clin Invest. 2018;128(7):2702\u201312. https:\/\/doi.org\/10.1172\/JCI97949.","journal-title":"J Clin Invest"},{"issue":"12","key":"1431_CR31","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1161\/01.atv.20.12.2614","volume":"20","author":"XC Jiang","year":"2000","unstructured":"Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2614\u20138. https:\/\/doi.org\/10.1161\/01.atv.20.12.2614.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"1431_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000672","volume":"5","author":"AA Hicks","year":"2009","unstructured":"Hicks AA, Pramstaller PP, Johansson A, Vitart V, Rudan I, Ugocsai P, et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet. 2009;5(10): e1000672. https:\/\/doi.org\/10.1371\/journal.pgen.1000672.","journal-title":"PLoS Genet"},{"issue":"11","key":"1431_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s42255-019-0134-8","volume":"1","author":"SA Summers","year":"2019","unstructured":"Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides. Nat Metab. 2019;1(11):1051\u20138. https:\/\/doi.org\/10.1038\/s42255-019-0134-8.","journal-title":"Nat Metab"},{"issue":"25","key":"1431_CR34","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967\u201376. https:\/\/doi.org\/10.1093\/eurheartj\/ehw148.","journal-title":"Eur Heart J"},{"issue":"5","key":"1431_CR35","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","volume":"64","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen PK, Zhou Y, Sadevirta S, Leivonen M, Arola J, Ore\u0161i\u010d M, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;64(5):1167\u201375. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.002.","journal-title":"J Hepatol"},{"issue":"3","key":"1431_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.039.","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"1431_CR37","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012.","journal-title":"J Hepatol"},{"issue":"6","key":"1431_CR38","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusio K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005\u201323. https:\/\/doi.org\/10.1002\/hep.25762.","journal-title":"Hepatology"},{"issue":"6","key":"1431_CR39","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/hep.24403","volume":"53","author":"P Angulo","year":"2011","unstructured":"Angulo P. Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts. Hepatology. 2011;53(6):1792\u20134. https:\/\/doi.org\/10.1002\/hep.24403.","journal-title":"Hepatology"},{"key":"1431_CR40","doi-asserted-by":"publisher","DOI":"10.1100\/2012\/496453","author":"T Ohki","year":"2012","unstructured":"Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Sci World J. 2012. https:\/\/doi.org\/10.1100\/2012\/496453.","journal-title":"Sci World J"},{"key":"1431_CR41","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.2147\/DDDT.S224688","volume":"13","author":"Y Luo","year":"2019","unstructured":"Luo Y, Yang P, Li Z, Ohsugi M, Yoshida H, Toda N, et al. Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways. Drug Des Devel Ther. 2019;13:4065\u201374. https:\/\/doi.org\/10.2147\/DDDT.S224688.","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"1431_CR42","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/dom.12748","volume":"18","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, et al. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes Obes Metab. 2016;18(12):1217\u201325. https:\/\/doi.org\/10.1111\/dom.12748.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1431_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335. https:\/\/doi.org\/10.1007\/s00125-015-3844-9.","journal-title":"Diabetologia"},{"issue":"1","key":"1431_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","volume":"6","author":"B Wang","year":"2021","unstructured":"Wang B, Wu L, Chen J, Dong L, Chen C, Wen C, et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther. 2021;6(1):94. https:\/\/doi.org\/10.1038\/s41392-020-00443-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1431_CR45","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.3390\/ijms19113285","volume":"19","author":"T Sonnweber","year":"2018","unstructured":"Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic acid metabolites in cardiovascular and metabolic diseases. Int J Mol Sci. 2018;19(11):3285. https:\/\/doi.org\/10.3390\/ijms19113285.","journal-title":"Int J Mol Sci"},{"key":"1431_CR46","doi-asserted-by":"publisher","first-page":"591819","DOI":"10.3389\/fendo.2020.591819","volume":"11","author":"AA Hajeyah","year":"2020","unstructured":"Hajeyah AA, Griffiths WJ, Wang Y, Finch AJ, O\u2019Donnell VB. The biosynthesis of enzymatically oxidized lipids. Front Endocrinol. 2020;11:591819.","journal-title":"Front Endocrinol"},{"key":"1431_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009379","volume":"7","author":"R Bret\u00f3n-Romero","year":"2018","unstructured":"Bret\u00f3n-Romero R, Weisbrod RM, Feng B, Holbrook M, Ko D, Stathos MM, et al. Liraglutide treatment reduces endothelial endoplasmic reticulum stress and insulin resistance in patients with diabetes mellitus. JAHA. 2018;7: e009379. https:\/\/doi.org\/10.1161\/JAHA.118.009379.","journal-title":"JAHA"},{"key":"1431_CR48","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1161\/ATVBAHA.120.315766","volume":"11","author":"M Ruuth","year":"2021","unstructured":"Ruuth M, Lahelma M, Luukkonen PK, Lorey MB, Qadri S, S\u00e4devirta S, et al. Overfeeding saturated fat increases LDL (low-density lipoprotein) aggregation susceptibility while overfeeding unsaturated fat decreases proteoglycan-binding of lipoproteins. Arterioscler Thromb Vasc Biol. 2021;11:2823\u201336. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315766.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01431-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01431-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01431-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T14:05:52Z","timestamp":1639749952000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01431-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1431"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01431-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"13 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The regional ethics committees at both participating centers reviewed and approved the trial protocol, and the study followed the International Conference on Harmonization Good Clinical Practice guidelines. All subjects provided written informed consent before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}